EA202092573A1 - Композиции и способы обнаружения и лечения рака желудка - Google Patents

Композиции и способы обнаружения и лечения рака желудка

Info

Publication number
EA202092573A1
EA202092573A1 EA202092573A EA202092573A EA202092573A1 EA 202092573 A1 EA202092573 A1 EA 202092573A1 EA 202092573 A EA202092573 A EA 202092573A EA 202092573 A EA202092573 A EA 202092573A EA 202092573 A1 EA202092573 A1 EA 202092573A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
compositions
gastric cancer
detection
treatment
Prior art date
Application number
EA202092573A
Other languages
English (en)
Inventor
Александр Приёр
Original Assignee
Прогастрин Э Кансер С.А Р.Л.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Прогастрин Э Кансер С.А Р.Л. filed Critical Прогастрин Э Кансер С.А Р.Л.
Publication of EA202092573A1 publication Critical patent/EA202092573A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/595—Gastrins; Cholecystokinins [CCK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Настоящее изобретение относится к способам диагностики рака желудка in vitro и к композициям и способам для профилактики или лечения рака желудка, где композиции содержат антитело, связывающееся с прогастрином, и способы включают применение антитела, связывающегося с прогастрином.
EA202092573A 2016-02-05 2017-01-02 Композиции и способы обнаружения и лечения рака желудка EA202092573A1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16305131 2016-02-05

Publications (1)

Publication Number Publication Date
EA202092573A1 true EA202092573A1 (ru) 2021-05-31

Family

ID=55310770

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092573A EA202092573A1 (ru) 2016-02-05 2017-01-02 Композиции и способы обнаружения и лечения рака желудка

Country Status (1)

Country Link
EA (1) EA202092573A1 (ru)

Similar Documents

Publication Publication Date Title
MX2023000889A (es) Anticuerpos contra bcma y su uso para tratar el cancer y los trastornos inmunitarios.
EA202090104A1 (ru) Молекулы антител к cd73 и пути их применения
EA202091540A1 (ru) Антитела к lilrb2
EA201892294A1 (ru) Антитела и композиции против tim-3
CY1122510T1 (el) Μορια αντισωματος σε lag-3 και χρησεις αυτων
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
PH12016502061A1 (en) Novel antii-rnf43 antibodies and methods of use
EA201891527A1 (ru) Композиции и способы обнаружения и лечения рака пищевода
EA201791050A1 (ru) Конъюгаты антител и лекарственных средств
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
MX2018012493A (es) Métodos para controlar y tratar el cáncer.
EA201790529A1 (ru) Новые антитела против mfi2 и способы их применения
EA201891528A1 (ru) Композиции и способы обнаружения и лечения рака желудка
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
EA201992318A1 (ru) Композиции и способы для диагностики и лечения рака предстательной железы с использованием молекулы, связывающей прогастрин
MX2022011972A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
EA201990978A1 (ru) Антитела против pd-1